ArticleCrystal growth & design2025
Nonmimetic Gels Direct Novel Crystallization Behavior of Lenalidomide.
Article in Crystal growth & design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crystallization within supramolecular gels can yield distinct solid-state outcomes compared with conventional solution-phase methods, including the formation of novel crystal forms or selectively crystallizing one crystal form from a concomitant mixture. In several cases, tailoring the molecular structure of a gelator to mimic a pharmaceutical substrate has facilitated crystallization control, where nonmimetic gelators had no influence on the crystallization outcome compared to the solution phase. In this study, we investigate the crystallization behavior of lenalidomide within both mimetic and nonmimetic gels. Crystallization in a cyclopentanone gel using a nonmimetic gelator led to the discovery of a novel cyclopentanone hemisolvate, inaccessible via solution-phase crystallization. Additionally, an ethanol gel of the same gelator promoted selective crystallization of metastable Form 4 in ethanol, in contrast to the thermodynamically favored Form 1 obtained from solution. Gel-phase crystallization using a drug-mimetic gelator produced no deviation from the solution-phase polymorphic outcomes, in contrast to previously reported examples. Solution-state NMR studies showed no evidence of strong interactions between lenalidomide and either gelator, suggesting that the spatial arrangement of the nonmimetic gel fibers and/or possible confinement effects, rather than solution association, plays a critical role in directing crystallization behavior.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.